Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Sees Significant Increase in Short Interest

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the recipient of a significant growth in short interest during the month of August. As of August 15th, there was short interest totaling 208,900 shares, agrowthof262.0% from the July 31st total of 57,700 shares. Currently,14.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 2,270,000 shares, the days-to-cover ratio is presently 0.1 days. Based on an average daily trading volume, of 2,270,000 shares, the days-to-cover ratio is presently 0.1 days. Currently,14.0% of the shares of the stock are sold short.

Bluejay Diagnostics Trading Up 0.6%

Shares of Bluejay Diagnostics stock opened at $1.37 on Wednesday. The stock has a market capitalization of $2.04 million, a price-to-earnings ratio of -0.01 and a beta of 0.48. Bluejay Diagnostics has a 1-year low of $1.26 and a 1-year high of $12.45. The firm’s 50-day moving average price is $1.52 and its two-hundred day moving average price is $2.28.

Bluejay Diagnostics (NASDAQ:BJDX) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($1.41) earnings per share for the quarter.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.